Zydus receives final approval from the USFDA for Ephedrine Sulfate Injection

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection USP, 50 mg/mL single-dose vials (USRLD: Akovaz® Injection).

Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara (India).

Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States (IQVIA MAT Mar. 2023).

The group now has 368 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 516.05 as compared to the previous close of Rs. 517.70. The total number of shares traded during the day was 9354 in over 812 trades.

The stock hit an intraday high of Rs. 522.00 and intraday low of 515.00. The net turnover during the day was Rs. 4850560.00.

(*as of 31st December 2022)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 USFDA FinalApproval EphedrineSulfateInjection